Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|February 13, 2014

Agilent Technologies, Cell Line Genetics Collaborate

Agilent Technologies and Cell Line Genetics will collaborate on services for regenerative medicine and cancer research.

Agilent Technologies reported its collaboration with Cell Line Genetics (CLG), a provider of cell-line characterization and quality assurance services. CLG will develop high-throughput, genomic characterization workflows to confirm and monitor the integrity of cell lines for translational and regenerative medicine research. The workflows will be based upon Agilent’s custom, targeted CGH+SNP microarrays and SureFISH technology.

CLG selected Agilent’s genome-wide CGH+SNP microarrays for their capability, in a predictable high-throughput environment, to detect amplifications, deletions, and cell line clonality with high sensitivity. CLG will use FISH assays to confirm aberrations identified down to the single-cell level. This approach provides a means of characterizing genome integrity and purity.

For cancer cell line characterization, CLG will offer array CGH (aCGH) services as it is able to simultaneously detect a large number of anomalies more accurately, with higher sensitivity, and with better coverage than traditional cytogenetics. In addition, when using aCGH, CLG can offer a faster turnaround time to customers.
After testing more than 15,000 stem cell lines, CLG found that 20% showed aneuploidy, and 60-70% of those were mosaic. Most significantly, the cells harboring genomic anomalies can have a proliferative advantage and overtake the culture, compromising the validity of study data and resulting in the loss of samples, time and funds.

Source: Cell Line Genetics


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.